Senate passes medication amendments aimed at preserving 340B patient access

The Utah Senate on Tuesday approved a substitute version of Senate Bill 69, medication amendments, aimed at preserving patient access to drugs purchased at discounted 340B prices by hospitals, clinics and tribal health providers.

Sponsor Senator Evan J. Vickers, presenting the substitute, said the 340B program "was created in 1992" and allows certain health care facilities, known in federal law as covered entities, to purchase outpatient drugs at a discounted price and use the savings to stretch limited federal resources. He told colleagues the dispute centers on some drug manufacturers that limit the program’s contract pharmacies for specific products — effectively restricting where patients can get discounted medications inside Utah.

Supporters said the bill does not expand federal authority or create a new subsidy; instead it seeks to ensure covered entities and their patients statewide retain access to discounted drugs when manufacturers put limits on contract-pharmacy arrangements. Vickers said the list of affected drugs has grown — "was 35," he said, and he had just learned another manufacturer added a drug — and that the measure would bar manufacturers from enforcing a one-contract-pharmacy rule that would block access in parts of the state.

Opponents, chiefly manufacturers and representatives of some industry groups, pressed concerns about program scope and commercial relationships; the transcript records negotiation attempts and legal risk. Senator Vickers acknowledged manufacturers have filed suits in other states after similar laws; he said some courts have so far sided with states but at least one case remains stayed.

After debate and a substitution process, the Senate substituted the bill (sixth substitute) and then approved it on a roll-call vote. The final tally reported on the floor was 26 yeas, 1 nay and 2 absent.

The bill’s supporters said the change preserves access to discounted drugs for rural hospitals, federally qualified health centers, tribal health facilities and other covered entities that rely on 340B savings to serve patients who are uninsured or underinsured. Manufacturers’ representatives told the Senate they opposed the bill and had sought different compromises during weeks of negotiation.

Senator Vickers and other backers said the law would not create a new taxpayer cost because 340B discounts are commercial discounts the manufacturer extends to covered entities; rather, the bill is designed to stop actions that could restrict where patients may fill discounted prescriptions.

The bill now moves to the Utah House for further consideration.

Ending: The Senate’s action keeps in place a state-level mechanism, supporters said, to protect 340B access inside Utah while legal challenges play out elsewhere. The transcript records both continued negotiations and an explicit warning from the sponsor that manufacturers were already litigating similar laws in other states.